



ImmunID Technologies Announces Divpenia® Poster Presentation at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

Grenoble, Lyon (France), Nov. 28, 2011 – ImmunID, the immune repertoire diversity company, today announced a presentation at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The event will be held on December 6-10, 2011 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Poster # P2-12-10 entitled, “Low TCR Diversity (Divpenia®) Is a Prognosis Factor of Overall Survival in Metastatic Breast Cancer” will be presented on Thursday, December 8, 2011 from 7:00am to 9:00am CST during Poster Session 2.

About Divpenia®

Divpenia® is a clinical state of reduced T and/or B lymphocytes immune diversity that correlates with a higher risk of infection & mortality and consequently a reduced treatment efficiency (www.divpenia.com). Depending on the indication, Divpenia® can be used as a biomarker for patient stratification, early diagnosis, prognosis and prediction of response to treatment. Over 700 patients have already been included in validation studies conducted by ImmunID in collaboration with partners.

About ImmunID

ImmunID is engaged in advancing personalized medicine through the development of molecular diagnostics products. ImmunID uses the immune repertoire diversity as a universal biomarker of health status and treatment efficiency. ImmunID looks at the disease/patient relationship differently, from an immunological perspective, to determine the patient’s ability to respond to a treatment, to support the clinical decision, and to ultimately achieve better clinical outcomes. ImmunID aims to demonstrate the clinical utility of Divpenia® in Oncology and Infectious Diseases and to bring this biomarker all the way to the medical practice, ultimately making a difference in the patient’ lives. The company also provides immune monitoring services to biopharmaceutical companies and clinical research centers worldwide.